Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• Amylyx Pharmaceuticals Inc AMLX.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of 7 cents. The mean expectation of four analysts for the quarter was for a loss of 52 cents per share. Wall Street expected results to range from -59 cents to -46 cents per share.

• Revenue rose 100.6% to $-665.00 thousand from a year ago; analysts expected zero.

• Amylyx Pharmaceuticals Inc's reported EPS for the quarter was a loss of 55 cents​.

• The company reported a quarterly loss of $37.55 million.

• Amylyx Pharmaceuticals Inc shares had fallen by 20.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $10.00

This summary was machine generated from LSEG data March 4 at 03:18 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)